Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dutch national guidelines for locally recurrent rectal cancer.
Piqeur F, Creemers DMJ, Banken E, Coolen L, Tanis PJ, Maas M, Roef M, Marijnen CAM, van Hellemond IEG, Nederend J, Rutten HJT, Peulen HMU, Burger JWA. Piqeur F, et al. Among authors: maas m. Cancer Treat Rev. 2024 Jun;127:102736. doi: 10.1016/j.ctrv.2024.102736. Epub 2024 Apr 19. Cancer Treat Rev. 2024. PMID: 38696903 Review.
Optimisation of Organ Preservation treatment strategies in patients with rectal cancer with a good clinical response after neoadjuvant (chemo)radiotherapy: Additional contact X-ray brachytherapy versus eXtending the observation period and local excision (OPAXX) - protocol for two multicentre, parallel, single-arm, phase II studies.
Geubels BM, van Triest B, Peters FP, Maas M, Beets GL, Marijnen CAM, Custers PA, Rutten HJT, Theuws JCM, Verrijssen AE, Cnossen JS, Burger JWA, Grotenhuis BA. Geubels BM, et al. Among authors: maas m. BMJ Open. 2023 Dec 30;13(12):e076866. doi: 10.1136/bmjopen-2023-076866. BMJ Open. 2023. PMID: 38159950 Free PMC article.
Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial.
Verweij ME, Tanaka MD, Kensen CM, van der Heide UA, Marijnen CAM, Janssen T, Vijlbrief T, van Grevenstein WMU, Moons LMG, Koopman M, Lacle MM, Braat MNGJA, Chalabi M, Maas M, Huibregtse IL, Snaebjornsson P, Grotenhuis BA, Fijneman R, Consten E, Pronk A, Smits AB, Heikens JT, Eijkelenkamp H, Elias SG, Verkooijen HM, Schoenmakers MMC, Meijer GJ, Intven M, Peters FP. Verweij ME, et al. Among authors: maas m. BMJ Open. 2023 Jun 15;13(6):e065010. doi: 10.1136/bmjopen-2022-065010. BMJ Open. 2023. PMID: 37321815 Free PMC article.
The sigmoid take-off as a landmark to distinguish rectal from sigmoid tumours on MRI: Reproducibility, pitfalls and potential impact on treatment stratification.
Bogveradze N, Lambregts DMJ, El Khababi N, Dresen RC, Maas M, Kusters M, Tanis PJ, Beets-Tan RGH; MRI rectal study group. Bogveradze N, et al. Among authors: maas m. Eur J Surg Oncol. 2022 Jan;48(1):237-244. doi: 10.1016/j.ejso.2021.09.009. Epub 2021 Sep 20. Eur J Surg Oncol. 2022. PMID: 34583878
An International Expert-Based Consensus on the Definition of a Clinical Near-Complete Response After Neoadjuvant (Chemo)radiotherapy for Rectal Cancer.
Custers PA, Beets GL, Bach SP, Blomqvist LK, Figueiredo N, Gollub MJ, Martling A, Melenhorst J, Ortega CD, Perez RO, Smith JJ, Lambregts DMJ, Beets-Tan RGH, Maas M. Custers PA, et al. Among authors: maas m. Dis Colon Rectum. 2024 Jun 1;67(6):782-795. doi: 10.1097/DCR.0000000000003209. Epub 2024 May 2. Dis Colon Rectum. 2024. PMID: 38701503
MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial.
Görgec B, Hansen IS, Kemmerich G, Syversveen T, Abu Hilal M, Belt EJT, Bosscha K, Burgmans MC, Cappendijk VC, D'Hondt M, Edwin B, van Erkel AR, Gielkens HAJ, Grünhagen DJ, Gobardhan PD, Hartgrink HH, Horsthuis K, Klompenhouwer EG, Kok NFM, Kint PAM, Kuhlmann K, Leclercq WKG, Lips DJ, Lutin B, Maas M, Marsman HA, Meijerink M, Meyer Y, Morone M, Peringa J, Sijberden JP, van Delden OM, van den Bergh JE, Vanhooymissen IJS, Vermaas M, Willemssen FEJA, Dijkgraaf MGW, Bossuyt PM, Swijnenburg RJ, Fretland ÅA, Verhoef C, Besselink MG, Stoker J; CAMINO Study Group. Görgec B, et al. Among authors: maas m. Lancet Oncol. 2024 Jan;25(1):137-146. doi: 10.1016/S1470-2045(23)00572-7. Epub 2023 Dec 8. Lancet Oncol. 2024. PMID: 38081200
Neurohospitalist Core Competencies.
Wold JJ, Robertson J, Jeevarajan JA, Knox MG, Thatikunta P, Solorzano GE, Galetta K, Dujari S, Goyal T, Ehrlich ME, Donnelly JP, Marriott E, Mandge VA, Dhoot RS, Luedke MW, Maas MB, Yu MY, Toledano M, Mustafa R, Palaganas JL, Kvam K, Dugue R, Meltzer E, Touma L, Shah MP, Douglas VC, Orjuela K, Scott BJ, Klein JP, Likosky DJ, Simpson JR, Richie MB, Dohle C, Morris JG, Gold CA. Wold JJ, et al. Among authors: maas mb. Neurohospitalist. 2024 Nov 26:19418744241297187. doi: 10.1177/19418744241297187. Online ahead of print. Neurohospitalist. 2024. PMID: 39610897 Free PMC article. Review.
Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma.
Shoumariyeh K, Csernalabics B, Salimi Alizei E, Reinscheid M, Giese S, Ciminski K, Kochs G, Schwemmle M, Lang-Meli J, Maas M, Roehlen N, Karl V, Graeser A, Sogukpinar O, von Metzler I, Grathwohl D, Rasche L, Hebart H, Kull M, Emmerich F, Waller CF, Duyster J, Engelhardt M, Hartmann TN, Bengsch B, Boettler T, Neumann-Haefelin C, Hofmann M, Thimme R, Luxenburger H. Shoumariyeh K, et al. Among authors: maas m. Vaccines (Basel). 2024 Nov 1;12(11):1249. doi: 10.3390/vaccines12111249. Vaccines (Basel). 2024. PMID: 39591152 Free PMC article.
1,196 results